{
    "paper_id": "4e71da667d102d51bf6536baf99b66b10a0b5ea8",
    "metadata": {
        "title": "Journal Pre-proof Clinical considerations for managing dermatology patients on systemic immunosuppressive and/or biologic therapy during COVID-19 pandemic Title: Clinical considerations for managing dermatology patients on systemic 3 immunosuppressive and/or biologic therapy during COVID-19 pandemic 4 5",
        "authors": [
            {
                "first": "Daniela",
                "middle": [
                    "P"
                ],
                "last": "Sanchez",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Boston University School of Medicine",
                    "location": {
                        "settlement": "Boston",
                        "region": "Massachusetts"
                    }
                },
                "email": ""
            },
            {
                "first": "Robert",
                "middle": [
                    "S"
                ],
                "last": "Kirsner",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Hadar",
                "middle": [],
                "last": "Lev-Tov",
                "suffix": "",
                "affiliation": {},
                "email": "hlevtov@med.miami.edu"
            },
            {
                "first": "Phillip",
                "middle": [],
                "last": "Frost",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Dr",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "word count: 200 27",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Capsule summary word count: 49 28",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "rates associated with biologics were overall comparable to placebo prior to the COVID-19 54 outbreak however, medication and disease specific subtleties exist. For example, anti-TNFs pose 55 a risk for viral infections. However, differing results were seen in treatment of psoriasis versus 56 HS. Secukinumab was associated with increased URI but not the other IL-17 inhibitors. 57",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Tofacitinib treatment of psoriatic patients resulted in increase incidence of URI compared to 58 placebo. Cyclosporine is immunosuppressive, however, in management of PG, URI were not 59 reported in a RCT but 11% (N=6) of patients on prednisolone experienced infections requiring 60 hospital admissions compared to none in the cyclosporine arm. Placebo controlled RCTs of other 61 systemic immunosuppressive medications for dermatological indications are lacking. 62",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Considering the data presented in this report, the vital protective function of the skin and 63 mucosa, and the relatively lower doses used in dermatology, it is reasonable to conclude that 64 patients with severe dermatological conditions requiring systemic therapies are overall likely to 65 benefit from improved intact cutaneous function afforded by these medications. In high risk 66 patients, consideration of stopping tofacitinib and secukinumab may be warranted. 67",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "We encourage all patients to focus on infection prevention strategies. If symptoms arise, 68",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "we advise a stepwise approach (figure 1). 87 ",
            "cite_spans": [
                {
                    "start": 42,
                    "end": 44,
                    "text": "87",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "/ 25 (30.1) -Chronic urticaria 41",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "American Academy of Dermatology. Managing your practice through the COVID-19 100 outbreak. https://www.aad.org/member/practice/managing/coronavirus. University of Miami clinical considerations for Managing Patients on systemic 106immunosuppressive and/or biologic therapy (SIBT) During COVID-",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "To the Editor: Concern about COVID-19 in patients treated with systemic 47 immunosuppressive and/or biologic therapy (SIBT) exists. 1,10 However, there are no data on the 48 effects of COVID-19 infection in this population. 1,12 We examined randomized controlled trials 49 The results presented in table 1 and the reader is directed to the supplemental materials 52 for a detailed discussion. Briefly, our findings suggest that upper respiratory infection (URI) 53",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Active infections remain a contraindication for SIBT. 69 Practical considerations should apply including avoiding medications with frequent blood 70 testing, switching to self-injected medication, and moving visits to telehealth. Discontinuation of 71 SIBT may result in disease exacerbation and loss of therapeutic response upon reintroduction. 72 We hope these guidelines help dermatologists navigate therapy, as deemed appropriate by the 73 Wu, Min-Hu Chen, Implications of COVID-19 for patients with pre-existing digestive 91 American College of Rheumatology. A Message from the ACR about Coronavirus 97 Disease 2019 (COVID-19). https://www.rheumatology.org/announcements. Accessed 98 March 16, 2020.",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Rate of infections with SIBT for dermatological indications. Green cells suggest no increased URI, red cells suggest",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}